VIAF

Virtual International Authority File

Search

Leader     00000nz a2200037n 45 0
001     WKP|Q73072909  (VIAF cluster)  (Authority/Source Record)
003     WKP
005     20241120235812.0
008     241120nneanz||abbn n and d
035 ‎‡a  (WKP)Q73072909‏
024 ‎‡a  0000-0001-6471-5564‏ ‎‡2  orcid‏
024 ‎‡a  7101718403‏ ‎‡2  scopus‏
035 ‎‡a  (OCoLC)Q73072909‏
100 0 ‎‡a  Fernando Araújo‏ ‎‡c  researcher (ORCID 0000-0001-6471-5564)‏ ‎‡9  en‏
400 0 ‎‡a  Araújo F‏ ‎‡c  wetenschapper‏ ‎‡9  nl‏
670 ‎‡a  Author's A new interministerial strategy for the promotion of healthy eating in Portugal: implementation and initial results‏
670 ‎‡a  Author's Acute HIV infection presenting as hemophagocytic syndrome with an unusual serological and virological response to ART‏
670 ‎‡a  Author's An integrated program of extracorporeal membrane oxygenation‏
670 ‎‡a  Author's An integrated program of extracorporeal membrane oxygenation (ECMO) assisted cardiopulmonary resuscitation and uncontrolled donation after circulatory determination of death in refractory cardiac arrest‏
670 ‎‡a  Author's Assessment of the Anticoagulation Activity of Apixaban‏
670 ‎‡a  Author's Blood group-antigen profile predicted by molecular biology in Munchausen syndrome by proxy‏
670 ‎‡a  Author's Blood group antigen profile predicted by molecular biology-use of real-time polymerase chain reaction to genotype important KEL, JK,RHD, and RHCE alleles.‏
670 ‎‡a  Author's Cardiovascular Risk Factors in Acromegaly: What's the Impact of Disease Control?‏
670 ‎‡a  Author's Costs and utilization of treatment in patients with hemophilia‏
670 ‎‡a  Author's Detection of HIV-1 subtype G using Cobas Ampliscreen test‏
670 ‎‡a  Author's [Erratum: Using Pricing Policies to Promote Public Health: The Sugar Sweetened Beverages Taxation Experience in Portugal]‏
670 ‎‡a  Author's Evaluation of NucliSens-AmpliScreen methodology to detect subtypes G of HIV-1 and 4c/4d of HCV in the screening of blood donors.‏
670 ‎‡a  Author's [Evolution of residual risk for HIV, HCV and HBV, from 1999 to 2010, in blood donations of the Centro Hospitalar S. João, EPE, Porto, Portugal].‏
670 ‎‡a  Author's Genotyping Dombrock alleles in Portuguese blood donors by real-time PCR.‏
670 ‎‡a  Author's Genotyping RHD zygosity using real-time polymerase chain reaction‏
670 ‎‡a  Author's Hyperhomocysteinemia, MTHFR C677T genotype and low folate levels: a risk combination for acute coronary disease in a Portuguese population‏
670 ‎‡a  Author's Impact of an individualized prophylaxis approach on young adults with severe hemophilia.‏
670 ‎‡a  Author's Implementação de um sistema regional de resposta emergente ao acidente vascular cerebral: primeiros resultados‏
670 ‎‡a  Author's Molecular epidemiology and prevalence of drug resistance-associated mutations in newly diagnosed HIV-1 patients in Portugal.‏
670 ‎‡a  Author's Nurses knowledge in Transfusion Medicine in a Portuguese university hospital: the impact of an education‏
670 ‎‡a  Author's Perinatally acquired HIV-2 infection diagnosed at 15 and 24 years of age‏
670 ‎‡a  Author's Phenotyping Rh/Kell and risk of alloimmunization in haematological patients‏
670 ‎‡a  Author's Prevalence of Parvovirus B19 and Hepatitis A virus in Portuguese blood donors.‏
670 ‎‡a  Author's Rapid genotyping of the major alleles at the Duffy‏
670 ‎‡a  Author's Rapid genotyping of the major alleles at the Duffy (FY) blood group locus using real-time fluorescence polymerase chain reaction.‏
670 ‎‡a  Author's Re: Prediction of the fetal Kell blood group reduces aggressive interventions.‏
670 ‎‡a  Author's Reactivation of hepatitis B virus without core antibody‏
670 ‎‡a  Author's Real-time PCR assays for high-throughput blood group genotyping.‏
670 ‎‡a  Author's Regarding the article: Postoperative recovery of blood in patients undergoing total knee or hip arthroplasty‏
670 ‎‡a  Author's Soluble selectins, sICAM, sVCAM, and angiogenic proteins in different activity groups of patients with inflammatory bowel disease.‏
670 ‎‡a  Author's The clinical phenotype modulation of haemophilia by prothrombotic gene mutations.‏
670 ‎‡a  Author's The PORtromb Project: prothrombin G20210A mutation and venous thromboembolism in young people‏
670 ‎‡a  Author's Transmission of HIV-2: another perspective‏
670 ‎‡a  Author's Transmission of HIV Drug Resistance and the Predicted Effect on Current First-line Regimens in Europe‏
670 ‎‡a  Author's [Using Pricing Policies to Promote Public Health: The Sugar Sweetened Beverages Taxation Experience in Portugal]‏
670 ‎‡a  Author's Weak D type 2 is the most prevalent weak D type in Portugal.‏
909 ‎‡a  (scopus) 7101718403‏ ‎‡9  1‏
909 ‎‡a  (orcid) 0000000164715564‏ ‎‡9  1‏
912 ‎‡a  transmissionofhivdrugresistanceandthepredictedeffectoncurrent1lineregimensineurope‏ ‎‡A  Transmission of HIV Drug Resistance and the Predicted Effect on Current First-line Regimens in Europe‏ ‎‡9  1‏
919 ‎‡a  rapidgenotypingofthemajorallelesattheduffyfybloodgrouplocususingrealtimefluorescencepolymerasechainreaction‏ ‎‡A  Rapid genotyping of the major alleles at the Duffy (FY) blood group locus using real-time fluorescence polymerase chain reaction.‏ ‎‡9  1‏
919 ‎‡a  rapidgenotypingofthemajorallelesattheduffy‏ ‎‡A  Rapid genotyping of the major alleles at the Duffy‏ ‎‡9  1‏
919 ‎‡a  prevalenceofparvovirusb19andhepatitisavirusinportugueseblooddonors‏ ‎‡A  Prevalence of Parvovirus B19 and Hepatitis A virus in Portuguese blood donors.‏ ‎‡9  1‏
919 ‎‡a  phenotypingrhkellandriskofalloimmunizationinhaematologicalpatients‏ ‎‡A  Phenotyping Rh/Kell and risk of alloimmunization in haematological patients‏ ‎‡9  1‏
919 ‎‡a  perinatallyacquiredhiv2infectiondiagnosedat15and24yearsofage‏ ‎‡A  Perinatally acquired HIV-2 infection diagnosed at 15 and 24 years of age‏ ‎‡9  1‏
919 ‎‡a  nursesknowledgeintransfusionmedicineinaportugueseuniversityhospitaltheimpactofaneducation‏ ‎‡A  Nurses knowledge in Transfusion Medicine in a Portuguese university hospital: the impact of an education‏ ‎‡9  1‏
919 ‎‡a  molecularepidemiologyandprevalenceofdrugresistanceassociatedmutationsinnewlydiagnosedhiv1patientsinportugal‏ ‎‡A  Molecular epidemiology and prevalence of drug resistance-associated mutations in newly diagnosed HIV-1 patients in Portugal.‏ ‎‡9  1‏
919 ‎‡a  implementacaodeumsistemaregionalderespostaemergenteaoacidentevascularcerebralprimeirosresultados‏ ‎‡A  Implementação de um sistema regional de resposta emergente ao acidente vascular cerebral: primeiros resultados‏ ‎‡9  1‏
919 ‎‡a  impactofanindividualizedprophylaxisapproachonyoungadultswithseverehemophilia‏ ‎‡A  Impact of an individualized prophylaxis approach on young adults with severe hemophilia.‏ ‎‡9  1‏
919 ‎‡a  hyperhomocysteinemiamthfrc677tgenotypeandlowfolatelevelsariskcombinationforacutecoronarydiseaseinaportuguesepopulation‏ ‎‡A  Hyperhomocysteinemia, MTHFR C677T genotype and low folate levels: a risk combination for acute coronary disease in a Portuguese population‏ ‎‡9  1‏
919 ‎‡a  genotypingrhdzygosityusingrealtimepolymerasechainreaction‏ ‎‡A  Genotyping RHD zygosity using real-time polymerase chain reaction‏ ‎‡9  1‏
919 ‎‡a  genotypingdombrockallelesinportugueseblooddonorsbyrealtimepcr‏ ‎‡A  Genotyping Dombrock alleles in Portuguese blood donors by real-time PCR.‏ ‎‡9  1‏
919 ‎‡a  evolutionofresidualriskforhivhcvandhbvfrom1999to2010inblooddonationsofthecentrohospitalarsjoaoepeportoportugal‏ ‎‡A  [Evolution of residual risk for HIV, HCV and HBV, from 1999 to 2010, in blood donations of the Centro Hospitalar S. João, EPE, Porto, Portugal].‏ ‎‡9  1‏
919 ‎‡a  evaluationofnuclisensampliscreenmethodologytodetectsubtypesgofhiv1and4c4dofhcvinthescreeningofblooddonors‏ ‎‡A  Evaluation of NucliSens-AmpliScreen methodology to detect subtypes G of HIV-1 and 4c/4d of HCV in the screening of blood donors.‏ ‎‡9  1‏
919 ‎‡a  erratumusingpricingpoliciestopromotepublichealththesugarsweetenedbeveragestaxationexperienceinportugal‏ ‎‡A  [Erratum: Using Pricing Policies to Promote Public Health: The Sugar Sweetened Beverages Taxation Experience in Portugal]‏ ‎‡9  1‏
919 ‎‡a  detectionofhiv1subtypegusingcobasampliscreentest‏ ‎‡A  Detection of HIV-1 subtype G using Cobas Ampliscreen test‏ ‎‡9  1‏
919 ‎‡a  costsandutilizationoftreatmentinpatientswithhemophilia‏ ‎‡A  Costs and utilization of treatment in patients with hemophilia‏ ‎‡9  1‏
919 ‎‡a  cardiovascularriskfactorsinacromegalywhatstheimpactofdiseasecontrol‏ ‎‡A  Cardiovascular Risk Factors in Acromegaly: What's the Impact of Disease Control?‏ ‎‡9  1‏
919 ‎‡a  bloodgroupantigenprofilepredictedbymolecularbiologyuseofrealtimepolymerasechainreactiontogenotypeimportantkeljkrhdandrhcealleles‏ ‎‡A  Blood group antigen profile predicted by molecular biology-use of real-time polymerase chain reaction to genotype important KEL, JK,RHD, and RHCE alleles.‏ ‎‡9  1‏
919 ‎‡a  bloodgroupantigenprofilepredictedbymolecularbiologyinmunchausensyndromebyproxy‏ ‎‡A  Blood group-antigen profile predicted by molecular biology in Munchausen syndrome by proxy‏ ‎‡9  1‏
919 ‎‡a  assessmentoftheanticoagulationactivityofapixaban‏ ‎‡A  Assessment of the Anticoagulation Activity of Apixaban‏ ‎‡9  1‏
919 ‎‡a  integratedprogramofextracorporealmembraneoxygenationecmoassistedcardiopulmonaryresuscitationanduncontrolleddonationaftercirculatorydeterminationofdeathinrefractorycardiacarrest‏ ‎‡A  An integrated program of extracorporeal membrane oxygenation (ECMO) assisted cardiopulmonary resuscitation and uncontrolled donation after circulatory determination of death in refractory cardiac arrest‏ ‎‡9  1‏
919 ‎‡a  integratedprogramofextracorporealmembraneoxygenation‏ ‎‡A  An integrated program of extracorporeal membrane oxygenation‏ ‎‡9  1‏
919 ‎‡a  acutehivinfectionpresentingashemophagocyticsyndromewithanunusualserologicalandvirologicalresponsetoart‏ ‎‡A  Acute HIV infection presenting as hemophagocytic syndrome with an unusual serological and virological response to ART‏ ‎‡9  1‏
919 ‎‡a  newinterministerialstrategyforthepromotionofhealthyeatinginportugalimplementationandinitialresults‏ ‎‡A  A new interministerial strategy for the promotion of healthy eating in Portugal: implementation and initial results‏ ‎‡9  1‏
919 ‎‡a  weak500type2isthemostprevalentweak500typeinportugal‏ ‎‡A  Weak D type 2 is the most prevalent weak D type in Portugal.‏ ‎‡9  1‏
919 ‎‡a  usingpricingpoliciestopromotepublichealththesugarsweetenedbeveragestaxationexperienceinportugal‏ ‎‡A  [Using Pricing Policies to Promote Public Health: The Sugar Sweetened Beverages Taxation Experience in Portugal]‏ ‎‡9  1‏
919 ‎‡a  transmissionofhiv2anotherperspective‏ ‎‡A  Transmission of HIV-2: another perspective‏ ‎‡9  1‏
919 ‎‡a  portrombprojectprothrombing20210amutationandvenousthromboembolisminyoungpeople‏ ‎‡A  The PORtromb Project: prothrombin G20210A mutation and venous thromboembolism in young people‏ ‎‡9  1‏
919 ‎‡a  clinicalphenotypemodulationofhaemophiliabyprothromboticgenemutations‏ ‎‡A  The clinical phenotype modulation of haemophilia by prothrombotic gene mutations.‏ ‎‡9  1‏
919 ‎‡a  solubleselectinssicamsvcamandangiogenicproteinsindifferentactivitygroupsofpatientswithinflammatoryboweldisease‏ ‎‡A  Soluble selectins, sICAM, sVCAM, and angiogenic proteins in different activity groups of patients with inflammatory bowel disease.‏ ‎‡9  1‏
919 ‎‡a  regardingthearticlepostoperativerecoveryofbloodinpatientsundergoingtotalkneeorhiparthroplasty‏ ‎‡A  Regarding the article: Postoperative recovery of blood in patients undergoing total knee or hip arthroplasty‏ ‎‡9  1‏
919 ‎‡a  realtimepcrassaysforhighthroughputbloodgroupgenotyping‏ ‎‡A  Real-time PCR assays for high-throughput blood group genotyping.‏ ‎‡9  1‏
919 ‎‡a  reactivationofhepatitisbviruswithoutcoreantibody‏ ‎‡A  Reactivation of hepatitis B virus without core antibody‏ ‎‡9  1‏
919 ‎‡a  repredictionofthefetalkellbloodgroupreducesaggressiveinterventions‏ ‎‡A  Re: Prediction of the fetal Kell blood group reduces aggressive interventions.‏ ‎‡9  1‏
996 ‎‡2  ISNI|0000000083324326‏
996 ‎‡2  NUKAT|n 2007116745‏
996 ‎‡2  BLBNB|000432678‏
996 ‎‡2  BNF|18009348‏
996 ‎‡2  BNCHL|10000000000000000137083‏
996 ‎‡2  LC|n 2011214368‏
996 ‎‡2  BLBNB|000330703‏
996 ‎‡2  BLBNB|000600614‏
996 ‎‡2  ISNI|0000000479774817‏
996 ‎‡2  BNE|XX5488671‏
996 ‎‡2  PTBNP|1898058‏
996 ‎‡2  ISNI|0000000079961437‏
996 ‎‡2  ISNI|0000000403401424‏
996 ‎‡2  BNE|XX1410149‏
996 ‎‡2  ISNI|0000000114564470‏
996 ‎‡2  ISNI|0000000025359707‏
996 ‎‡2  ISNI|0000000069695606‏
996 ‎‡2  ISNI|0000000030555358‏
996 ‎‡2  BNCHL|10000000000000000121693‏
996 ‎‡2  SUDOC|266757847‏
996 ‎‡2  ISNI|0000000428306589‏
996 ‎‡2  PTBNP|133236‏
996 ‎‡2  BNF|12749370‏
996 ‎‡2  RERO|A006032760‏
996 ‎‡2  PTBNP|1438089‏
996 ‎‡2  PTBNP|287853‏
996 ‎‡2  DNB|133154653‏
996 ‎‡2  DNB|132615711‏
996 ‎‡2  ISNI|0000000440048623‏
996 ‎‡2  DNB|1204930015‏
996 ‎‡2  DNB|1057429112‏
996 ‎‡2  NTA|318603780‏
996 ‎‡2  ISNI|0000000501095483‏
996 ‎‡2  ISNI|0000000434595399‏
996 ‎‡2  ISNI|0000000506832913‏
996 ‎‡2  LC|no2020009134‏
996 ‎‡2  LC|no2014069519‏
996 ‎‡2  ISNI|0000000070019066‏
996 ‎‡2  SUDOC|109435885‏
996 ‎‡2  BLBNB|000600591‏
996 ‎‡2  ISNI|0000000069105637‏
996 ‎‡2  SUDOC|254146368‏
996 ‎‡2  DNB|133677109‏
996 ‎‡2  PTBNP|6278‏
996 ‎‡2  RERO|A005759608‏
996 ‎‡2  ISNI|0000000120890205‏
996 ‎‡2  DNB|1242671277‏
996 ‎‡2  ISNI|0000000070809180‏
996 ‎‡2  LC|n 2021250721‏
996 ‎‡2  DNB|1154889122‏
996 ‎‡2  ISNI|0000000069501381‏
996 ‎‡2  LC|no2007045086‏
996 ‎‡2  ISNI|0000000052938069‏
996 ‎‡2  BNC|981060918511406706‏
996 ‎‡2  LC|n 2024251495‏
996 ‎‡2  LC|nr 98021498‏
996 ‎‡2  BLBNB|000524751‏
996 ‎‡2  BLBNB|000614420‏
996 ‎‡2  BLBNB|001492980‏
996 ‎‡2  PTBNP|193036‏
996 ‎‡2  SUDOC|163914060‏
996 ‎‡2  BLBNB|000286339‏
996 ‎‡2  PTBNP|1476163‏
996 ‎‡2  LC|n 85007809‏
996 ‎‡2  PTBNP|6575‏
996 ‎‡2  BNE|XX832480‏
996 ‎‡2  SUDOC|267297734‏
996 ‎‡2  PTBNP|1752454‏
996 ‎‡2  LC|n 84072607‏
996 ‎‡2  ISNI|0000000068615176‏
996 ‎‡2  LC|n 2022046561‏
996 ‎‡2  PTBNP|321152‏
996 ‎‡2  LC|no2019126796‏
996 ‎‡2  BLBNB|001119814‏
996 ‎‡2  BLBNB|000448475‏
996 ‎‡2  LC|n 90612779‏
996 ‎‡2  DNB|1279989696‏
996 ‎‡2  SUDOC|256888167‏
996 ‎‡2  LC|no2013047742‏
996 ‎‡2  PTBNP|1363212‏
996 ‎‡2  LC|n 80140576‏
996 ‎‡2  PTBNP|1503075‏
996 ‎‡2  DNB|1057540781‏
996 ‎‡2  BLBNB|000242363‏
996 ‎‡2  BLBNB|000457873‏
996 ‎‡2  BAV|495_78790‏
996 ‎‡2  LC|nr2003004371‏
996 ‎‡2  ISNI|0000000069322041‏
996 ‎‡2  NII|DA14625594‏
996 ‎‡2  PTBNP|557646‏
996 ‎‡2  ISNI|0000000070411244‏
996 ‎‡2  PTBNP|6293‏
996 ‎‡2  PTBNP|6296‏
996 ‎‡2  LC|n 2021027635‏
996 ‎‡2  ISNI|0000000113039279‏
996 ‎‡2  LC|n 2006072420‏
996 ‎‡2  LC|nr 96041591‏
996 ‎‡2  RERO|A008995568‏
996 ‎‡2  ISNI|0000000069322025‏
996 ‎‡2  PTBNP|1725817‏
996 ‎‡2  BNE|XX1651114‏
996 ‎‡2  PTBNP|1633127‏
996 ‎‡2  ISNI|0000000089993571‏
996 ‎‡2  LC|no2020143197‏
996 ‎‡2  PTBNP|1196350‏
996 ‎‡2  RERO|A002935236‏
996 ‎‡2  BNF|17852924‏
996 ‎‡2  PTBNP|6284‏
996 ‎‡2  LC|no2014137497‏
996 ‎‡2  PTBNP|92125‏
996 ‎‡2  PTBNP|150435‏
996 ‎‡2  ISNI|0000000069322033‏
996 ‎‡2  BNF|16640337‏
996 ‎‡2  BNE|XX1194703‏
996 ‎‡2  DNB|1321822391‏
996 ‎‡2  PTBNP|217227‏
996 ‎‡2  DNB|1132735238‏
996 ‎‡2  PTBNP|1222308‏
996 ‎‡2  DNB|1056539224‏
996 ‎‡2  DNB|1055187758‏
996 ‎‡2  LC|n 87865401‏
996 ‎‡2  DNB|1292262060‏
996 ‎‡2  PTBNP|1223362‏
996 ‎‡2  ISNI|0000000062701401‏
997 ‎‡a  0 0 lived 0 0‏ ‎‡9  1‏